Related Experiment Videos
Stem cell transplantation for multiple myeloma: current status and future directions
Humberto Caldera1, Sergio Giralt
1Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Current Hematology Reports
|June 26, 2004
Summary
High-dose chemotherapy with autologous stem cell transplantation is a proven treatment for multiple myeloma. This review examines transplant benefits, optimal procedures, and the potential role of allogeneic transplantation.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- High-dose chemotherapy or chemoradiation with autologous stem cell transplantation is a recognized therapy for multiple myeloma.
- Randomized trials confirm autografting as the preferred initial treatment for patients under 65.
Purpose of the Study:
- To review the benefits of stem cell transplantation in multiple myeloma.
- To discuss the optimal procedures for autologous stem cell transplantation.
- To evaluate the potential role of allogeneic stem cell transplantation.
Main Methods:
- Review of randomized trials and existing literature on stem cell transplantation for multiple myeloma.
- Analysis of patient selection criteria for transplant.
- Discussion of procedural aspects and outcomes.
Main Results:
- Autologous stem cell transplantation is established as a standard of care for eligible multiple myeloma patients.
- Evidence supports its role in initial therapy for younger patients.
- The review addresses key questions regarding transplant efficacy and future directions.
Conclusions:
- Autologous stem cell transplantation is a cornerstone therapy for multiple myeloma.
- Further investigation into allografting may offer additional therapeutic options.
- Optimal patient selection and procedure refinement are crucial for maximizing outcomes.